Myelodysplastic Syndrome (MDS)-Associated Cytogenetic Abnormalities in Pediatric Chronic Myelogenous Leukemia

被引：3

作者：

Kumar, Kirthi R. ^{[1
]}

Koduru, Prasad ^{[1
]}

Timmons, Charles ^{[1
]}

Monaghan, Sara ^{[1
]}

Cavalier, MaryEllen ^{[2
]}

Luu, Hung S. ^{[1
]}

机构：

[1] UT Southwestern Med Ctr, Childrens Med Ctr, Dept Pathol, Parkland Hlth & Hosp Syst, Dallas, TX USA

[2] UT Southwestern Med Ctr, Childrens Med Ctr, Dept Pediat, Div Hematol Oncol, Dallas, TX USA

来源：

PEDIATRIC BLOOD & CANCER | 2013年 / 60卷 / 11期

关键词：

chronic myelogenous leukemia; cytogenetics; molecular genetics; myelodysplastic syndrome; CHRONIC MYELOID-LEUKEMIA; GENOMIC INSTABILITY; IMATINIB MESYLATE; NEGATIVE CELLS; BCR-ABL;

D O I：

10.1002/pbc.24645

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myelogenous leukemia (CML) is very rare in the pediatric population. We report the case of a 2-year-old female with CML and concurrent myelodysplastic syndrome (MDS) associated cytogenetic abnormalities. The co-existence of t(9;22) and chromosomal deletions that are associated with MDS poses a unique diagnostic challenge. Given the reported association of t(9;22) and genomic instability, we hypothesize that the chromosomal deletions represent clonal evolution of the CML. Pediatr Blood Cancer 2013;60:E146-E148. (c) 2013 Wiley Periodicals, Inc.

引用

页码：E146 / E148

页数：3

共 13 条

[1] How I treat childhood CML [J].

Andolina, Jeffrey R. ;

Neudorf, Steven M. ;

Corey, Seth J. .

BLOOD, 2012, 119 (08) :1821-1830

[2] Tyrosine Kinase Targeted Treatment of Chronic Myelogenous Leukemia and Other Myeloproliferative Neoplasms [J].

Bisen, Ajit ;

Claxton, David F. .

IMPACT OF GENETIC TARGETS ON CANCER THERAPY, 2013, 779 :179-196

[3] BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia [J].

Burke, B. A. ;

Carroll, M. .

LEUKEMIA, 2010, 24 (06) :1105-1112

[4] Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β [J].

Canitrot, Y ;

Lautier, D ;

Laurent, G ;

Fréchet, M ;

Ahmed, A ;

Turhan, AG ;

Salles, B ;

Cazaux, C ;

Hoffmann, JS .

ONCOGENE, 1999, 18 (17) :2676-2680

[5] Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and management [J].

Jabbour, Elias ;

Kantarjian, Hagop .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (11) :1038-1045

[6] Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia [J].

Kovitz, Craig ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo ;

Abruzzo, Lynne V. ;

Cortes, Jorge .

BLOOD, 2006, 108 (08) :2811-2813

[7] Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells [J].

Larsson, Nina ;

Billstrom, Rolf ;

Lilljebjorn, Henrik ;

Lassen, Carin ;

Richter, Johan ;

Ekblom, Marja ;

Fioretos, Thoas .

CANCER GENETICS AND CYTOGENETICS, 2010, 199 (02) :89-95

[8] Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib [J].

Loriaux, M ;

Deininger, M .

LEUKEMIA & LYMPHOMA, 2004, 45 (11) :2197-2203

[9] Chronic myeloid leukaemia as a model of disease evolution in human cancer [J].

Melo, Junia V. ;

Barnes, David J. .

NATURE REVIEWS CANCER, 2007, 7 (06) :441-453

[10] Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation [J].

Millot, F ;

Guilhot, J ;

Nelken, B ;

Leblanc, T ;

De Bont, ES ;

Békassy, AN ;

Gadner, H ;

Sufliarska, S ;

Stary, J ;

Gschaidmeier, H ;

Guilhot, F ;

Suttorp, M .

LEUKEMIA, 2006, 20 (02) :187-192

← 1 2 →